Search results
Results from the WOW.Com Content Network
ALK, Hepatocyte Growth Factor Receptor (HGFR, c-Met), and Recepteur d'Origine Nantais (RON) inhibitor. Non-small cell lung cancer Lymphopenia, neutropenia, hypophosphataemia, hypokalaemia, peripheral neuropathy, blood clots, QT interval prolongation, bradycardia, pneumonia, pneumonitis, kidney cyst, ARDS and liver failure.
Antineoplastic agents in chemotherapy are designed to eliminate rapidly dividing cancer cells, but they can also damage healthy structures, including the peripheral nervous system. [1] CIPN involves various symptoms such as tingling, pain, and numbness in the hands and feet. [ 2 ]
Many classes of antineoplastic drugs act on intracellular components and pathways, like DNA, nuclear components, meaning that they need to enter the cancer cells. The p-glycoprotein (P-gp), or the multiple drug resistance protein, is a phosphorylated and glycosylated membrane transporter that can shuttle drugs out of the cell, thereby ...
An alkylating antineoplastic agent is an alkylating agent used in cancer treatment that attaches an alkyl group (C n H 2n+1) to DNA. [ 1 ] Since cancer cells, in general, proliferate faster and with less error-correcting than healthy cells, cancer cells are more sensitive to DNA damage—such as being alkylated.
This mechanism leads to specific patterns of damage in DNA, which can kill cancer cells but can also increase the risk of secondary tumors developing. [6] Platinum-based antineoplastic agents are sometimes described as "alkylating-like" due to similar effects as alkylating antineoplastic agents, although they do not have an alkyl group. [7]
Additionally, those who are responsible for disposing antineoplastic drugs in health care facilities are also at risk of exposure. [ 178 ] Dermal exposure is thought to be the main route of exposure due to the fact that significant amounts of the antineoplastic agents have been found in the gloves worn by healthcare workers who prepare, handle ...
This list focuses on the hazard linked to the agents. This means that while carcinogens are capable of causing cancer, it does not take their risk into account, which is the probability of causing a cancer, given the level of exposure to this carcinogen. [2] The list is up to date as of January 2024. [3]
Cell-cycle nonspecific antineoplastic agents (CCNS) refer to a class of pharmaceuticals that act as antitumor agents at all or any phases of the cell cycle. [ 1 ] Alkylating antineoplastic agent and anthracyclins are two examples.